Imugene gets FDA IND approval for Phase-1 trial of PD1-Vaxx
Category: #healthcare  By Mateen Dalal  Date: 2020-11-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Imugene gets FDA IND approval for Phase-1 trial of PD1-Vaxx

Imugene Ltd., a biotechnology firm that specializes in cancer immunotherapy, has recently bagged an investigational new drug (IND) approval from the US Food and Drug Administration (FDA) to commence the Phase-1 clinical study of PD1-Vaxx, one of its major immunotherapy candidates, in the United States.

As per reports, the approval enables Imugene to begin patient dosing and recruitment for its US Phase-1 clinical trial in non-small cell lung cancer (NSCLC) patients. Reportedly, New Jersey’s Hackensack University Medical Center will be the first hospital in the country to commence patient dosing for this trial.

Other US clinical sites will follow Hackensack University later this year. These clinics include Ohio State University Medical Center and Mayo Clinic in Phoenix, Arizona. The main goal of this Phase-1 study is to establish safety along with an ideal biological dose as a monotherapy and to measure immune response and efficacy.

Speaking on the move, Leslie Chong, CEO and Managing Director, said that receiving an IND approval from the FDA for PD1-Vaxx comes as a crucial step forward for the company. Moreover, commencing of the US study marks as a substantial milestone for the company as well as for the clinicians treating severe lung cancer in the country. Accomplishing this goal adds to Imugene’s dedication and perseverance as it continues to strengthen its commercial and clinical potential.

As of now, Imugene has enough funds to proceed with its human studies for PD1-Vaxx and CF33 treatments in the near-term. It will also be able to continue with the enrolment of patients for the HER-Vaxx Phase 2 trial.

Back in September, Imugene had published its balance sheet along with a $5.7 million option underwriting deal which offers holders an option to buy shares in the firm at a price of 2.6 cents per share. This agreement supports Imugene’s financial position and strengthens its existing cash balance of $30.1 million.

Source Credit: https://www.proactiveinvestors.com/companies/news/932862/imugene-receives-fda-ind-approval-for-phase-1-clinical-trial-of-new-checkpoint-immunotherapy-pd1-vaxx-in-usa-932862.html

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

AstraZeneca’s COVID-19 vaccine manufacturing error clouds trial data
AstraZeneca’s COVID-19 vaccine manufacturing error clouds trial data
By Mateen Dalal

AstraZeneca and Oxford University have recently encountered a manufacturing error of their experimen...

Singapore Airlines raises $500M with the help of 10-year bonds
Singapore Airlines raises $500M with the help of 10-year bonds
By Mateen Dalal

SIA (Singapore Airlines), a flag carrier airline of the country of Singapore, has reportedly raised ...

New TMG 360 Media to optimize time to market for Healthtech companies
New TMG 360 Media to optimize time to market for Healthtech companies
By Mateen Dalal

TMG 360 Media, a novel digital platform created for driving brand awareness, strategic partnerships,...